2025 Retina Update, Part 1: Injectables in the Medical Retina Space

01/23/25 • 43 min

Drs. Ashkan Abbey and Ehsan Rahimy join host Dr. Jay Sridhar to discuss recent developments in the medical retina and injectable space, including faricimab versus high-dose aflibercept, biosimilars for ranibizumab and aflibercept, off-label bevacaziumb shortages, dry age-related macular degeneration (AMD) therapies, private equity acquisitions, and the new drug pipeline.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Previous Episode

Botulinum Toxin in Strabismus

Pediatric ophthalmologists Drs. Michelle Cabrera and Alejandra de Alba join host Dr. Ben Young to discuss the pros and cons of using botulinum toxin (Botox) for treating patients with strabismus, and whether every pediatric ophthalmologist—or even general ophthalmologist—should have this technique in their toolbox.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Next Episode

2025 Retina Update, Part 2: Photobiomodulation, OCT and OCTA Reimbursement, and Surgical Advances

Drs. M. Ali Khan and Ajay Kuriyan join host Dr. Jay Sridhar to discuss updates in the retina space, including the FDA approval of photobiomodulation for dry age-related macular degeneration (AMD), OCT and OCTA reimbursement changes, and surgical technology advances.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.